(KZR) – Momentum Movers
-
Kezar Life Sciences (KZR) Climbs 35% Following Positive Results from Phase 2 Trial Evaluating Zetomipzomib for Treatment of Patients with LN
-
Kezar Life Sciences (KZR) Climbs 47% Following Interim Results from the MISSION Phase 2 Trial
-
Back to KZR Stock Lookup